The main strategies include: (1) Improving the pharmacokinetic properties of existing Dectin-1 agonists to enhance Dectin-1-dependent anti-tumor immunity; (2) interfering with Dectin-1 signaling to reverse the tumor immune-suppressive microenvironment; (3) utilizing Dectin-1 as a delivery system to target immune cells for delivering other anti-tumor agents; (4) and combining Dectin-1 with other anti-tumor agents to strengthen anti-tumor immune responses through various mechanisms. Here, CLEC7A is linked to neoplasm.